EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Gastrointestinal Toxicity of Antibody Drug Conjugates (ADCs) in Metastatic Breast Cancer: A Pooled Analysis

Rebecca Pedersini, Martina Buffoni, Fausto Petrelli, Antonio Ghidini, Pierluigi di Mauro, Vito Amoroso, Maria Chiara Parati, Lara Laini, Deborah Cosentini, Greta Schivardi, Giuseppe Ippolito, Alfredo Berruti und 1 weitere

Clinical Breast Cancer · 2024

DOI: 10.1016/j.clbc.2024.04.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Breast Cancer, 2024. Verfasst von Rebecca Pedersini und 12 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy; SSVD Breast Unit, ASST-Spedali Civili of Brescia, Brescia, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Immunoconjugates, Gastrointestinal Diseases, Ado-Trastuzumab Emtansine. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fondazione Beretta.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trastuzumab emtansine (T-DM1), sacituzumab govitecan (SG), and trastuzumab deruxtecan (T-DXd) are three ADCs approved for the treatment of metastatic breast cancer (MBC). Since gastrointestinal toxicities have been commonly observed with these drugs in clinical trials, a pooled analysis evaluating gastrointestinal adverse events (AEs) in patients with MBC treated with ADCs in clinical trials was performed. PubMed, Embase, and the Cochrane Library were searched from inception until May 2023 for phase II and III clinical trials reporting frequency and severity of gastrointestinal AEs during treatment with ADCs. Data were retrieved for nausea, vomiting, diarrhea, constipation, and abdominal pain: overall and grade 3-4 toxicity rates according to NCI-CTCAE were collected and expressed as proportions. A pre-specified subgroup analysis according to the agent was also carried out. Fourteen studies, comprising 5608 patients, were included in the analysis. Gastrointestinal AEs were frequently registered with SG and T-DXd. A significantly higher frequency of nausea (65.6% with SG, 75% with T-DXd), vomiting (43.7% with SG, 45% with T-DXd), and diarrhea (59.7% with SG, 29% with T-DXd) was noticed with these ADCs compared to TDM-1. Furthermore, diarrhea was more frequently associated with SG (grade 3 in 7.5% of patients), while constipation and abdominal pain were less common. Gastrointestinal AEs, notably nausea and diarrhea, were frequently reported by MBC patients treated with SG and T-DXd in clinical trials. Since these ADCs are administered continuously until disease progression or occurrence of unbearable AEs, gastrointestinal toxicity may have a negative impact on patient quality of life. Therefore, appropriate management of gastrointestinal AEs is mandatory to ensure treatment efficacy and adherence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsImmunoconjugatesGastrointestinal DiseasesAdo-Trastuzumab EmtansineAntibodies, Monoclonal, HumanizedHumansFemaleTrastuzumabCamptothecinNauseaNeoplasm MetastasisAntineoplastic Agents, Immunological

Stichwörter der Autor:innen

Advanced breast cancerGastrointestinal adverse eventsSacituzumab govitecanTrastuzumab deruxtecan

Substanzen

ImmunoconjugatesAdo-Trastuzumab Emtansinesacituzumab govitecanAntibodies, Monoclonal, HumanizedTrastuzumabtrastuzumab deruxtecanCamptothecinAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy; SSVD Breast Unit, ASST-Spedali Civili of Brescia, Brescia, Italy.
  • Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy. Electronic address: martinabuffoni97@gmail.com.
  • Medical Oncology, Caravaggio Hospital, Treviglio, Italy.
  • Medical Oncology, Casa di Cura Igea, Milano, Italy.
  • Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy.

Förderung

  • Fondazione Beretta

Zitieren

APA

Pedersini, R., Buffoni, M., Petrelli, F., Ghidini, A., di Mauro, P., Amoroso, V., Parati, M. C., Laini, L., Cosentini, D., Schivardi, G., Ippolito, G., Berruti, A., & Laganà, M. (2024). Gastrointestinal Toxicity of Antibody Drug Conjugates (ADCs) in Metastatic Breast Cancer: A Pooled Analysis. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.04.003

Vancouver

Pedersini R, Buffoni M, Petrelli F, Ghidini A, di Mauro P, Amoroso V, et al. Gastrointestinal Toxicity of Antibody Drug Conjugates (ADCs) in Metastatic Breast Cancer: A Pooled Analysis. Clinical Breast Cancer. 2024. doi:10.1016/j.clbc.2024.04.003

BibTeX
@article{Pedersini2024,
  author = {Pedersini, Rebecca and Buffoni, Martina and Petrelli, Fausto and Ghidini, Antonio and di Mauro, Pierluigi and Amoroso, Vito and Parati, Maria Chiara and Laini, Lara and Cosentini, Deborah and Schivardi, Greta and Ippolito, Giuseppe and Berruti, Alfredo and Laganà, Marta},
  title = {Gastrointestinal Toxicity of Antibody Drug Conjugates (ADCs) in Metastatic Breast Cancer: A Pooled Analysis},
  journal = {Clinical Breast Cancer},
  year = {2024},
  doi = {10.1016/j.clbc.2024.04.003}
}
Kostenlos starten →